Clinical Trial: Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056790) titled 'Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer' on June 30.

Brief Summary: 68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Prostate CA

Intervention: DRUG: 68Ga-PSMA-CYC

Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT ...